Salofalk prolonged-release granules (mesalazine gastro-resistant prolonged-release granules) / Dr Falk - LARVOL DELTA

Inflammatory Bowel Disease in the elderly, a survey of elderly patient demographics, disease-related complications and compliance with vaccination and screening services (ECCO-IBD 2023) - "Infliximab and salofalk granules were the most prescribed IBD treatments. Skin cancer was the most common malignancy. There was suboptimal uptake with vaccinations and bowel screening."

Clinical • Compliance • Immunology • Inflammation • Inflammatory Bowel Disease

Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets. (PubMed, J Control Release) - "Through population pharmacokinetic (PK) analysis and in-vitro in-vivo correlation (IVIVC) modeling on the dissolution and BE data of a generic enteric-coated product (EM) and its reference Salofalk® 250 mg tablet (SM), we for the first time revealed the underlying mechanism of the high inter-subject variability for such delayed-release formulation...Since the BE purpose for mesalazine enteric-coated tablet focused on their comparable safety profiles, total absorbed mesalazine was recommended to be adopted for the development of the IVIVC model and BE evaluation for EM. All in all, our model-based approach has not only successfully identified the key factors that affect the BE of EM to guide its further formulation optimization, but also demonstrated the indispensable role of modeling in the development of generic pharmaceutical product at its early stages."

Journal • PK/PD data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis